Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update – Highlights continued execution across...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast OCALA, Fla., Nov...
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen®...
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update – Continued operational execution across...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast OCALA, Fla., Aug...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions Topline...
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions Preliminary...
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer...
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating...
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Company continues to execute...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast OCALA...
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관